Based on the aforementioned role of TGF-β in KD and the ability of RJX to suppress the production of IL-6, TNF-α, and TGF-β, we hypothesize that RJX will emerge as a clinically useful adjunct to the IV immunoglobulin therapy and best supportive care in pediatric COVID-19 patients who develop KD. This evidence concerns the gene TNF and COVID-19.